KR102611539B1 - Gsk-3 억제제 - Google Patents

Gsk-3 억제제 Download PDF

Info

Publication number
KR102611539B1
KR102611539B1 KR1020197018281A KR20197018281A KR102611539B1 KR 102611539 B1 KR102611539 B1 KR 102611539B1 KR 1020197018281 A KR1020197018281 A KR 1020197018281A KR 20197018281 A KR20197018281 A KR 20197018281A KR 102611539 B1 KR102611539 B1 KR 102611539B1
Authority
KR
South Korea
Prior art keywords
mmol
pyridazine
imidazo
pyridin
yield
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197018281A
Other languages
English (en)
Korean (ko)
Other versions
KR20190085112A (ko
Inventor
리처드 에이. 하츠
비제이 티. 아후자
프라산나 시바프라카삼
진 엠. 두보우치크
존 이. 마코르
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20190085112A publication Critical patent/KR20190085112A/ko
Application granted granted Critical
Publication of KR102611539B1 publication Critical patent/KR102611539B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020197018281A 2016-11-28 2017-11-27 Gsk-3 억제제 Active KR102611539B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662426630P 2016-11-28 2016-11-28
US62/426,630 2016-11-28
PCT/US2017/063230 WO2018098411A1 (en) 2016-11-28 2017-11-27 Gsk-3 inhibitors

Publications (2)

Publication Number Publication Date
KR20190085112A KR20190085112A (ko) 2019-07-17
KR102611539B1 true KR102611539B1 (ko) 2023-12-06

Family

ID=60655129

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018281A Active KR102611539B1 (ko) 2016-11-28 2017-11-27 Gsk-3 억제제

Country Status (8)

Country Link
US (1) US10774086B2 (https=)
EP (1) EP3544980B1 (https=)
JP (1) JP6977038B2 (https=)
KR (1) KR102611539B1 (https=)
CN (1) CN110225912B (https=)
ES (1) ES2896938T3 (https=)
MA (1) MA46888A (https=)
WO (1) WO2018098411A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012136776A1 (en) 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors
WO2013059594A1 (en) * 2011-10-20 2013-04-25 Sirtris Pharmaceuticals, Inc. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29823A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
US20090170847A1 (en) * 2006-01-23 2009-07-02 Seung Chul Lee Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same
US20100292205A1 (en) * 2006-08-23 2010-11-18 Pfizer Inc. Pyrimidone Compounds As GSK-3 Inhibitors
US8053574B2 (en) * 2007-07-18 2011-11-08 Novartis Ag Organic compounds
CN105849098A (zh) * 2013-11-06 2016-08-10 百时美施贵宝公司 Gsk-3抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012136776A1 (en) 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors
WO2013059594A1 (en) * 2011-10-20 2013-04-25 Sirtris Pharmaceuticals, Inc. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators

Also Published As

Publication number Publication date
JP2019535790A (ja) 2019-12-12
KR20190085112A (ko) 2019-07-17
EP3544980A1 (en) 2019-10-02
US20190276463A1 (en) 2019-09-12
EP3544980B1 (en) 2021-10-13
ES2896938T3 (es) 2022-02-28
CN110225912B (zh) 2022-10-21
US10774086B2 (en) 2020-09-15
CN110225912A (zh) 2019-09-10
MA46888A (fr) 2021-06-02
JP6977038B2 (ja) 2021-12-08
WO2018098411A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
KR102725741B1 (ko) Rock의 억제제로서의 스피로헵탄 살리실아미드 및 관련 화합물
AU2016284654B9 (en) 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
EP3066093B9 (en) Gsk-3 inhibitors
JP6800885B2 (ja) イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
KR102292433B1 (ko) Gsk-3 억제제로서 유용한 치환된 피리딘 유도체
EP3661931A1 (en) Heterocyclic compound
KR20160132114A (ko) TrkA 키나제 억제제, 조성물 및 그의 방법
ES2878078T3 (es) Inhibidores de GSK-3
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
JP2020505397A (ja) Ｌｒｒｋ２キナーゼ活性を阻害するための化合物
KR102611539B1 (ko) Gsk-3 억제제
CN116981458A (zh) 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物
OA21024A (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190625

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201126

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230529

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231128

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231204

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231204

End annual number: 3

Start annual number: 1

PG1601 Publication of registration